You are here

Vabysmo

Roche lifts 2024 profit guidance on strong drug sales

Reuters

Thu, 07/25/24 - 11:27 am

Roche reports long-term data from diabetic macular edema treatment trial

Clinical Trials Arena

Thu, 07/18/24 - 11:25 am

clinical trials

diabetic macular edema

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Fierce Pharma

Mon, 07/8/24 - 11:47 am

Big Pharma’s most improved drugs: a new generation of blockbusters

Pharma Voice

Tue, 05/14/24 - 11:34 am

Roche reports data from Phase III retinal vein occlusion therapy trials

Clinical Trials Arena

Thu, 02/1/24 - 11:15 am

central retinal vein occlusion

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Fierce Pharma

Thu, 11/2/23 - 11:48 am

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

BioSpace

Fri, 10/27/23 - 11:34 am

retinal vein occlusion

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Reuters

Thu, 10/19/23 - 10:03 am

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Fierce Pharma

Wed, 10/11/23 - 10:13 am

retinal vein occlusion

Roche’s Vabysmo reports positive outcomes in multiple eye diseases

Clinical Trials Arena

Thu, 07/20/23 - 10:04 am

diabetic macular edema

wet age-related macular degeneration

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

BioSpace

Tue, 05/9/23 - 12:27 pm

retinal vein occlusion

Roche’s new eye drug pressures Eylea with strong launch

BioPharma Dive

Wed, 04/26/23 - 05:44 pm

Genentech opens up eye patients’ world with Vabysmo

Medical Marketing and Media

Thu, 04/20/23 - 11:40 pm

wet age-related macular degeneration

Trials cue up new use for Roche's eye disease drug Vabysmo

Pharmaphorum

Fri, 02/10/23 - 10:24 am

clinical trials

retinal vein occlusion

A year of two halves for US approvals

EP Vantage

Thu, 01/19/23 - 09:38 am

Bristol Myers Squibb

Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea

Fierce Pharma

Thu, 10/27/22 - 11:02 am

bispecific antibodies

Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate

Fierce Pharma

Mon, 07/25/22 - 10:00 pm

Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey

Fierce Pharma

Mon, 06/13/22 - 09:46 pm

The biggest launches of 2022: a reboot

EP Vantage

Mon, 02/14/22 - 10:48 am

Mirati Therapeutics

Bristol Myers Squibb

deucravacitinib

Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms

Fierce Pharma

Wed, 02/9/22 - 10:56 pm

Pages